Shares

Please see the below release from Avrobio.

 

Interested in participating? AVRO-RD-01-201 is a Phase2, open-label multinational clinical trial designed to evaluate the safety and efficacy of AVR-RD-01, an ex vivo, lentiviral vector-mediated gene therapy in individuals with Fabry disease.

Eligibility criteria:

  • Are between the ages of 16 and 50
  • Confirmed diagnosis of classic Fabry disease
  • Have had no enzyme replacement therapy (ERT) in the last 10 years and chaperone therapy naïve.

The AVRO trial is being conducted around the world and in sites in Canada. If you are interested in participating please send us a message at the Canadian Fabry Association or reach out directly to Dr. Aneal Khan at the Children’s Alberta Hospital at : aneal.khan@ahs.ca or Shelly Jelinski at Shelly.Jelinski@albertahealthservices.ca for more information. Please call Shelly at 403-955-7874

Study information website: https://avrobiofabrytrial.com/

Close

Contact Us

748 Kelly St
Thunder Bay ON P7E 2A1
Canada

If have any questions or would like to get involved, please fill in the form below.

Subscribe error, please review your email address.

Close

You're now subscribed, thank you!

Close

There was a problem with your submission. Please check the field(s) with red label below.

Close

Your message has been sent. We'll get back to you soon!

Close